Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV single-arm study of hawthorn extract WS 1442 in men with cardiovascular disease and erectile dysfunction
DRKS00010226Phase 4Terminated
- Sponsor
- Schwabe Group
- Start
- Mar 2016
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of crataegus special extract WS 1442 in heart failure (HF) and erectile dysfunction (ED), sponsored by Schwabe Group. Primary endpoints: Change in arterial microvascular structure, Change in arterial macrovascular function and 2 more. Started Mar 2016; status: terminated.
02
Drugs
crataegus special extract WS 1442
03
Conditions
heart failure (HF)erectile dysfunction (ED)
Beyond the preview
Go deeper on DRKS00010226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010226.